HFmrEF represents an intermediate clinical phenotype between HFrEF and HFpEF, but shares a higher prevalence of CAD and CAD-related mortality risk with HFrEF.
HFmrEF was an intermediate phenotype, except that CAD was more common in HFmrEF and HFrEF vs. HFpEF, crude all-cause mortality was lower in HFmrEF and HFrEF, adjusted all-cause mortality was lower in HFmrEF and HFpEF, and CAD portended a higher adjusted risk of death in HFmrEF and HFrEF.
Koh et al. (Mon,) studied this question.